AYTU BIOPHARMA, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AYTU BIOPHARMA, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $27.63M | Oct 6, 2020 |
| FY2020 | Jun 30, 2019 | $7.32M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $3.66M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $3.22M | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $2.56M | Aug 31, 2017 |
| FY2016 | Jun 30, 2015 | $261.8K | Sep 1, 2016 |
| FY2015 | Jun 30, 2014 | $58.9K | Sep 28, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $66.38M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $65.18M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $107.40M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $96.67M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $65.63M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $27.63M | Sep 28, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $45.83M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $49.05M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $66.63M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $52.28M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $29.20M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $19.35M | Sep 28, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($13.56M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($15.84M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | ($17.05M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($108.78M) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | ($58.29M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($13.62M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($27.13M) | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | ($10.19M) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($22.51M) | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | ($28.18M) | Aug 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($7.83M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($1.59M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | ($17.07M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($109.91M) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | ($58.87M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($21.13M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($16.85M) | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | ($19.70M) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($20.13M) | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | ($21.70M) | Aug 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.33M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $2.77M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $4.10M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $12.66M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $5.62M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $1.72M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $589.1K | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $167.6K | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $959.9K | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $6.13M | Aug 31, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $34.80M | Oct 6, 2020 |
| FY2020 | Jun 30, 2019 | $18.89M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $17.73M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $17.44M | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $8.52M | Aug 31, 2017 |
| FY2016 | Jun 30, 2015 | $3.98M | Sep 1, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($1.94M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($1.39M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | ($5.13M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($28.82M) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | ($25.96M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($28.37M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($13.83M) | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | ($15.94M) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($13.83M) | Sep 6, 2018 |
| FY2013 | Aug 31, 2013 | ($37.7K) | Nov 26, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $228.0K | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $329.0K | Sep 23, 2025 |
| FY2020 | Jun 30, 2020 | $0 | Oct 6, 2020 |
| FY2020 | Jun 30, 2019 | $59.8K | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $74.7K | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $111.6K | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $252.9K | Aug 31, 2017 |
| FY2016 | Jun 30, 2015 | $0 | Sep 1, 2016 |
| FY2015 | Jun 30, 2014 | $9.3K | Sep 28, 2015 |
| FY2013 | Aug 31, 2013 | $26.9K | Nov 26, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $124.18M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $118.10M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $136.46M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $137.62M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $265.67M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $153.29M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $34.72M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $21.06M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $15.00M | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $24.34M | Aug 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $97.11M | Oct 12, 2023 |
| FY2023 | Jun 30, 2022 | $93.32M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $128.10M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $58.28M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $27.63M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $7.64M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $11.00M | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $14.26M | Aug 31, 2017 |
| FY2016 | Jun 30, 2015 | $2.57M | Sep 1, 2016 |
| FY2015 | Jun 30, 2014 | $6.65M | Sep 28, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $18.97M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $27.72M | Sep 23, 2025 |
| FY2025 | Jun 30, 2023 | $39.36M | Sep 23, 2025 |
| FY2024 | Jun 30, 2022 | $44.31M | Sep 26, 2024 |
| FY2022 | Jun 30, 2021 | $137.57M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $95.02M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $7.09M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $13.42M | Oct 6, 2020 |
| FY2020 | Jun 30, 2017 | $4.00M | Sep 26, 2019 |
| FY2018 | Jun 30, 2016 | $10.09M | Sep 6, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2023 | $0 | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $0 | Oct 12, 2023 |
| FY2023 | Jun 30, 2021 | $65.80M | Oct 12, 2023 |
| FY2022 | Jun 30, 2020 | $28.09M | Sep 27, 2022 |
| FY2020 | Jun 30, 2019 | $0 | Oct 6, 2020 |
| FY2018 | Jun 30, 2017 | $238.4K | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $221.0K | Aug 31, 2017 |
| FY2016 | Jun 30, 2015 | $74.0K | Sep 1, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($333.54M) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | ($319.97M) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | ($304.13M) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | ($287.08M) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | ($178.30M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($120.01M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($106.39M) | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | ($79.26M) | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | ($69.07M) | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | ($46.56M) | Aug 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $30.95M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | $20.01M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | $22.99M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | $19.36M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | $49.65M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $48.08M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $11.04M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | $7.01M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | $802.3K | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | $8.05M | Aug 31, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $15.00M | Oct 12, 2023 |
| FY2022 | Jun 30, 2022 | $15.00M | Sep 27, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (2) | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | (2) | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | (5) | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | (74) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Sep 27, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | (5) | Oct 12, 2023 |
| FY2023 | Jun 30, 2022 | (74) | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Sep 27, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 8.98M | Sep 23, 2025 |
| FY2025 | Jun 30, 2024 | 5.97M | Sep 23, 2025 |
| FY2024 | Jun 30, 2023 | 5.52M | Sep 26, 2024 |
| FY2023 | Jun 30, 2022 | 1.93M | Oct 12, 2023 |
| FY2022 | Jun 30, 2021 | 27.49M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | 12.58M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | 17.54M | Oct 6, 2020 |
| FY2020 | Jun 30, 2018 | 1.79M | Sep 26, 2019 |
| FY2018 | Jun 30, 2017 | 41,244 | Sep 6, 2018 |
| FY2017 | Jun 30, 2016 | 187,098 | Aug 31, 2017 |